200 related articles for article (PubMed ID: 35120067)
1. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
Krawczyk N; Jent V; Hadland SE; Cerdá M
J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
[TBL] [Abstract][Full Text] [Related]
2. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
Corry B; Underwood N; Cremer LJ; Rooks-Peck CR; Jones C
Drug Alcohol Depend; 2022 Jul; 236():109495. PubMed ID: 35605533
[TBL] [Abstract][Full Text] [Related]
3. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
[TBL] [Abstract][Full Text] [Related]
4. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
[No Abstract] [Full Text] [Related]
5. Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States.
Paschen-Wolff MM; Velasquez R; Aydinoglo N; Campbell ANC
J Subst Abuse Treat; 2022 Sep; 140():108828. PubMed ID: 35749919
[TBL] [Abstract][Full Text] [Related]
6. Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior.
Mitchell P; Samsel S; Curtin KM; Price A; Turner D; Tramp R; Hudnall M; Parton J; Lewis D
Soc Sci Med; 2022 Jun; 302():114992. PubMed ID: 35512612
[TBL] [Abstract][Full Text] [Related]
7. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
[TBL] [Abstract][Full Text] [Related]
8. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
Dickson-Gomez J; Krechel S; Ohlrich J; Montaque HDG; Weeks M; Li J; Havens J; Spector A
Harm Reduct J; 2024 Feb; 21(1):52. PubMed ID: 38413972
[TBL] [Abstract][Full Text] [Related]
9. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
10. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
[TBL] [Abstract][Full Text] [Related]
11. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
[TBL] [Abstract][Full Text] [Related]
12. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
[TBL] [Abstract][Full Text] [Related]
13. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K
Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094
[TBL] [Abstract][Full Text] [Related]
14. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
15. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
[TBL] [Abstract][Full Text] [Related]
16. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
Treitler PC; Enich M; Reeves D; Crystal S
Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
[No Abstract] [Full Text] [Related]
17. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
18. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
[No Abstract] [Full Text] [Related]
19. Comparison between buprenorphine provider availability and opioid deaths among US counties.
Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R
J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537
[TBL] [Abstract][Full Text] [Related]
20. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
